
    
      The primary objective is to compare the antiviral efficacy of an early switch from a boosted
      PI/2NRTI regimen to Trizivir (after undetectability of HIV-RNA has been achieved on 2
      consecutive occasions) with uninterrupted use of the PI/2NRTI regimen for 96 weeks.
    
  